When families ask about memantine vs donepezil for Alzheimer’s, they’re usually hoping one of them is clearly better. The honest answer is that they work differently, they’re approved for different stages, and most patients who do well long-term end up on both.
That’s not a cop-out. It reflects how the FDA actually approved these drugs and what large trials have shown. Donepezil (Aricept) is a cholinesterase inhibitor approved for mild, moderate, and severe Alzheimer’s disease. Memantine (Namenda) is an NMDA receptor antagonist approved only for moderate to severe disease. Different mechanisms, different stages, different side effect profiles.
So the better question isn’t which drug wins. It’s which drug fits where your loved one is right now, and what the evidence from the National Institute on Aging and major trials actually shows.
How Each Drug Works
Donepezil blocks the enzyme that breaks down acetylcholine, a neurotransmitter critical for memory and attention. In Alzheimer’s, cholinergic neurons die off early, so propping up the remaining acetylcholine helps. Modestly. For a while.
Memantine works on a completely different system. It’s an NMDA receptor antagonist that dampens overactive glutamate signaling, which is thought to contribute to neuronal damage as the disease progresses. Think of donepezil as boosting a fading signal and memantine as protecting against excess noise.
This is why the memantine vs donepezil question often has a "both" answer in moderate-to-severe disease. They don’t compete. They target different problems.
Which Stage of Alzheimer’s Are You Treating?
Stage matters more than almost anything else in this comparison.
- Mild Alzheimer’s: Donepezil is the standard. Memantine isn’t FDA-approved here and trials in mild disease have been underwhelming.
- Moderate Alzheimer’s: Either drug is reasonable. Many specialists start donepezil first and add memantine when symptoms progress.
- Severe Alzheimer’s: Combination therapy (donepezil plus memantine) is often used. The fixed-dose combo Namzaric exists specifically for this.
A 2019 Cochrane review found donepezil produces small but measurable improvements in cognition and function across stages. Memantine trials show similar modest benefits, but mostly in moderate-to-severe disease. Neither drug stops progression. Both can buy time.
Side Effects: Where Memantine Usually Wins
This is where the memantine vs donepezil comparison gets more clear-cut. Memantine is generally easier to tolerate.
Common donepezil side effects:
- Nausea, diarrhea, loss of appetite (cholinergic effects)
- Vivid dreams or nightmares
- Muscle cramps
- Slow heart rate, which can be a real issue in older patients with conduction problems
- Weight loss
Common memantine side effects:
- Dizziness
- Headache
- Constipation
- Confusion (usually mild, usually transient)
In practice, what I see most often with donepezil is GI distress in the first few weeks and sleep disruption that families don’t connect to the medication until weeks later. With memantine, the complaints are usually milder. Patients with bradycardia, syncope, or a history of GI bleeding generally tolerate memantine better, which is one reason cardiologists sometimes push back on donepezil in frail elderly patients. The FDA prescribing information for donepezil carries warnings about both.
For a deeper look at donepezil specifically, our guide on what to expect from donepezil for Alzheimer’s walks through dosing and the first few weeks in detail.
Combination Therapy: The Realistic Long Game
Here’s what most families don’t realize at diagnosis: the memantine vs donepezil decision usually becomes a "when do we add the other one" decision within a couple of years.
Studies of combination therapy in moderate-to-severe Alzheimer’s, including the DOMINO-AD trial published in NEJM, suggest that continuing donepezil and adding memantine as disease progresses provides cognitive benefit beyond either drug alone. The combined regimen also seems to reduce nursing home placement rates in some analyses, though the data isn’t bulletproof.
If you’re comparing across the cholinesterase inhibitor class, our breakdowns of rivastigmine vs donepezil and galantamine vs donepezil cover the within-class differences. And for the broader dementia picture (vascular, Lewy body, mixed), our memantine vs donepezil for dementia comparison digs into the non-Alzheimer’s questions.
Cost and Practical Access
Both drugs are available as generics, and both are affordable on most insurance plans.
- Generic donepezil: typically $10 to $20 a month
- Generic memantine: typically $15 to $30 a month
- Namzaric (combo): often more expensive without good coverage
You can compare prices on generic memantine and donepezil at edrugstore.com, which is worth doing if your Part D plan put either drug on a higher tier this year.
Your prescriber will determine the right dose, but the general pattern is donepezil 5 mg once daily, increased to 10 mg after four to six weeks, and memantine titrated up over four weeks to 10 mg twice daily (or 28 mg extended-release once daily). Both drugs are taken long-term. Stopping abruptly often causes a noticeable decline within weeks.
When to Talk to Your Doctor
Bring it up sooner rather than later if you notice:
- Significant weight loss or persistent GI symptoms on donepezil
- New fainting episodes, dizziness, or slow pulse
- Worsening confusion after a memantine dose increase
- Sleep so disrupted that the caregiver can’t function
These are fixable problems most of the time. Dose changes, switching agents, or moving donepezil to morning instead of bedtime often resolve them.
The Bottom Line
In the memantine vs donepezil decision, donepezil is the first-line choice for mild Alzheimer’s and is approved across all stages. Memantine is reserved for moderate-to-severe disease and is generally easier on the gut and heart. For many patients, the real answer is sequential, donepezil first, memantine added later, with both continued as the disease progresses.
Talk to your prescriber or pharmacist about which fits your loved one’s stage, other medications, and tolerance profile. The memantine vs donepezil question rarely has a single right answer, but it almost always has a thoughtful one.
This article is for informational purposes only and is not medical advice. Always consult a licensed pharmacist or physician before starting, stopping, or changing any medication.
References
- National Institute on Aging, How Alzheimer’s Disease Is Treated, overview of FDA-approved treatments and stage-based recommendations.
- Cochrane Review: Donepezil for Dementia Due to Alzheimer’s Disease (2018), pooled trial data on donepezil’s cognitive and functional effects.
- FDA Prescribing Information for Donepezil (Aricept), official safety warnings and dosing.
- DOMINO-AD Trial, NEJM 2012, randomized data on continued donepezil and added memantine in moderate-to-severe Alzheimer’s.
Dr Steven Schlosser
Dr. Schlosser graduated from Lafayette College Phi Beta Kappa and attended Georgetown Medical School. He had 4 years of medical residency training at Tufts University in Boston in both Gynecology and Internal Medicine. He has had a spotless medical career for the past 40+ years and is Board Certified. Learn More